A Phase 3, Multicenter, Double Blind Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis,
Role: Investigator,
Celgene, Inc.,
(12/2024 - 12/2025)
Status: Approved